BoneDisease.gif Back grey_arrow_rt.gif
Recent articles on bone issues.
  1. Bone Update: Is It Still an Issue Without Tenofovir Disoproxil Fumarate? - (03/09/20)
  2. Bisphosphonates and lower mortality risk, Heart Disease & Bone Disease Associated in HIV+ - (12/04/19)
  3. Bone, Frailty, and Aging at CROI 2019 - Todd Brown, MD, PhD Division of Endocrinology, Diabetes, & Metabolism Johns Hopkins University - (05/31/19)
  4. IAS: Bone Mineral Density at the Hip Declines Twice as Quickly Among HIV-Infected Women than Men - (08/14/17)
  5. Bone Density, Microarchitecture, and Tissue Quality After Long-Term Treatment With Tenofovir/Emtricitabine or Abacavir/Lamivudine - (06/21/17)
  9. IAC: Monthly Vitamin D May Improve Bone Density in People With HIV - Mark Mascolini (07/28/14)
  10. CROI: Osteoporosis (bone), Frailty, and Vitamin D: CROI 2014 - Todd T. Brown, MD, PhD Division of Endocrinology, Diabetes, & Metabolism Johns Hopkins University - (04/01/14)
  11. CROI: Mechanism of Bone Disease in HIV and HCV: Impact of Tenofovir Exposure and Severity of Liver Disease - (04/01/14)
  12. Fracture risk in hepatitis C virus infected persons: results from the DANVIR cohort study; HIV & HCV/HIV Bone Loss - (03/19/14)
  13. CROI: Bone quality determination by ultrasonometry in young South African HIV-infected children - (03/10/14)
  14. CROI: Newborns Exposed to TDF in Utero Have Lower Bone Mineral Content in US - written by Mark Mascolini - (03/06/14)
  15. CROI: Rosuvastatin Improves Hip Bone Mineral Density but Worsens Insulin Resistance - (03/07/14)
  16. CROI: Vitamin D/Calcium Supplements Reduce Bone Loss by 50% When Starting EFV/TDF/FTC - written by Mark Mascolini - (03/10/14)
  17. CROI: Bone quality determination by ultrasonometry in young South African HIV-infected children - (03/10/14)
  18. CROI: Geriatric Syndromes are Common Among Older HIV-Infected Adults: in this group over age 50, 50% of participants had frailty or pre-frailty ay higher frequencies than HIV-negatives" - (03/10/14)
  19. CROI: Low Bone Mineral Density among Ugandan HIV infected patients on failing first line Antiretroviral Therapy; a sub-study of the EARNEST trial - (03/10/14)
  20. CROI: Lower Newborn Bone Mineral Content (BMC) Associated with Maternal Use of Tenofovir Disoproxil Fumarate (TDF) - (03/10/14)
  21. CROI: Comparison of Two Doses of Zoledronic Acid for the Treatment of Osteoporosis in HIV Infected Patients. Results of a Randomized Open Label Study (VIHZOL Study) - (03/10/14)
  22. CROI: Longitudinal Changes in Free Testosterone among Older HIV-infected and HIV-uninfected Men: "FT decreased similarly over a 6-year interval in older HIV infected and HIV-uninfected men" - (03/10/14)
  23. CROI: Frailty, Inflammation and Mortality among Aging HIV-Infected and At-Risk Injection Drug Users - (03/10/14)
  24. CROI: Atazanavir/Cobicistat Fixed-Dose Combination is Bioequivalent to the Separate Agents - (03/10/14)
  25. CROI: Hand osteoarthritis, a joint disorder frequent and more severe HIV-1 patients : METAFIB OA Study - (03/10/14)
  26. CROI: Low Bone Mineral Density is Associated with Increased Risk of Incident Fracture in HIV-infected Adults "highlighting the potential value of DEXA screening in this population"......median age 42[35-48]....36% osteopenia/2.9% osteoporosis - (03/10/14)
  27. CROI: Bone Density Changes after Antiretroviral Initiation with Protease Inhibitors or Raltegravir - (03/10/14)
  28. CROI: New Fracture Risk and FRAX 10-Year Probability of Fracture in HIV-infected Adults - (03/10/14)
  29. EACS: Twice-Higher Latest Vitamin D Almost Halves Odds of Death in EuroSIDA - Written by Mark Mascolini - (10/21/13)
  30. IAS: Number of regimens rather than cumulative exposure to antiretrovirals associated with lower bone mineral density in HIV-positive subjects - (07/22/13)
  31. Incident fractures in HIV-infected individuals: a systematic review and meta-analysis - (07/22/13)
  32. High sensitive CRP is an independent risk factor for all fractures and vertebral fractures in elderly men: The MrOS Sweden study - (07/20/13)
  33. CROI: CROI 2013: Comorbidities- Aging/Kidney/Heart/Belly Fat/HCV/Bone/Statins/Frailty - (05/27/13)
  34. CROI: Update from 20th CROI: Bones, Vitamin D, Frailty - Todd T. Brown, MD, PhD Association Professor of Medicine and Epidemiology Division of Endocrinology and Metabolism Johns Hopkins University - (04/01/13)
  35. Chronic viral hepatitis is associated with low bone mineral density in HIV-infected patients, ANRS CO 3 Aquitaine Cohort - (02/04/13)
  36. Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART Body Composition substudy - (01/12/13)
  37. IAC: Fractures at Earlier Age in HIV+ Men Versus HIV-Negatives in MACS - Written by Mark Mascolini - (07/24/12)
  38. IAC: PIs, Proton Pump Inhibitors, Stroke Raise Fracture Risk in HIV+ Veterans - Written by Mark Mascolini - (07/24/12)
  39. Bone Loss in Young HIV+ Men 'Lifestyle Risk' - (06/20/12)
  40. Bone Loss in the HIV-Infected Patient: Evidence, Clinical Implications, and Treatment Strategies- Review - (06/14/12)
  41. Bisphosphonates for Osteoporosis - Where Do We Go from Here?/Duration of Therapy - Perspective - (05/17/12)
  42. Effects of Intravenous Zoledronate on Bone Turnover and Bone Density Persist for at Least Five Years in HIV-Infected Men - (04/11/12)
  43. CROI: CROI Report: Bones, Frailty, and Vitamin D - written by Todd Brown, MD, PhD Associate Professor of Medicine Division of Endocrinology and Metabolism Johns Hopkins University - (03/19/12)
  44. Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial - (02/14/12)
  45. HIV infection induces age-related changes to monocytes and innate immune activation in young males which persist despite cART - (02/08/12)
  46. Fractures/Bone Loss in HIV: 'traditional risk factors more important' but HIV & ARV exposure have some impact, Vit D may Improve Bone Health & Reduce Fracture Risk, New Studies - (02/08/12)
  47. Overall benefit of antiretroviral treatment on the risk of fracture in HIV: nested case control analysis in a health-insured population - (02/08/12)
  48. Vitamin D and UVB Radiation: How Much Is Necessary? "Exposure to a UVB dose of 1 SED every second week to ~88% body area is sufficient for maintaining summer 25(OH)D levels during the winter." - pdf attached - (02/03/12)
  49. Vitamin D Supplementation, HIV, HAART, Bone Health, Fractures - (01/23/12)
  50. Vitamin D Improves Bone Health/Reduces Fracture Risk-Bone Loss: IOM, Endocrine Society - How Much Vit D Supp?/Calcium - (01/23/12)
  51. Vitamin D, Calcium Intakes Guidelines - 3 Reports - (01/02/12)
  52. Vitamin D With or Without Calcium Supplementation for Prevention of Cancer and Fractures: An Updated Meta-analysis for the U.S. Preventive Services Task Force - (01/02/12)
  53. HIV+ & HIV/HCV(tripled) Have Higher Fracture Rates Compared to General Population in Denmark - (11/28/11)
  54. IAS: The Effect of Vitamin D on Falls: A Systematic Review and Meta-Analysis - (07/28/11)
  55. Low CD4 Count Is Associated With an Increased Risk of Fragility Fracture in HIV-Infected Patients - (06/20/11)
  56. Vitamin D Deficiency in HIV-Infected and HIV-Uninfected Women in the United States - (06/20/11)
  57. Vitamin D Ups Bisphosphonate Response (from Jules: and calcium levels too perhaps) - (06/13/11)
  58. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study: Vit D levels associated with HIV progression & mortality - (06/13/11)
  59. Premature aging seen as issue for AIDS survivors - (06/13/11)
  60. Increasing Clarity on Bone Loss Associated With Antiretroviral Initiation - editorial - (05/24/11)
  61. The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of US women - (05/24/11)
  62. Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202 - pdf attached - (05/24/11)
  63. Vitamin D is linked to carotid intima-media thickness and immune reconstitution in HIV-positive individuals: 'and to CD4 change after starting ART' - pdf attached - (05/19/11)
  64. Low Vitamin D Levels Seen in Parkinson's Patients - full text of study below - - (05/19/11)
  65. Vitamin D Status of HIV-Infected Women and Its Association with HIV Disease Progression, Anemia, and Mortality: "Women in the highest vitamin D quintile had a 42% lower risk of all-cause mortality, compared to the lowest quintile. Vitamin D status had a protective association with HIV disease progression, all-cause mortality" - (05/19/11)
  66. Bisphosphonate Use and Atypical Fractures of the Femoral Shaft - (05/07/11)
  67. Vitamin D3 Supplementation Decreases Parathyroid Hormone (PTH) in HIV-Infected Youth Being Treated with Tenofovir-Containing Combination Antiretroviral Therapy: Randomized, Double-blind, Placebo-controlled Multicenter Trial Adolescent Trials Network (ATN) study 063 - (03/29/11)
  68. CROI: Risk of Fractures Associated with HIV/Hepatitis C Coinfection - (03/28/11)
  69. CROI: Bone and Vitamin D at CROI 2011 - By Todd T. Brown, MD, PhD - (03/26/11)
  70. CROI: Bone & HIV CROI 2011 - (03/26/11)
  71. CROI: BMD Loss in HIV TDF PrEP - 2 studies - (03/22/11)
  72. CROI: Changes in bone biomarkers in antiretroviral naïve HIV-infected men randomised to nevirapine/lopinavir/ritonavir (NVP/LPV/r) or zidovudine/lamivudine/lopinavir/ritonavir (AZT/3TC/LPV/r) help explain limited loss of bone mineral density over first 12 months after antiretroviral therapy (ART) initiation (03/14/11)
  73. CROI: Firstline HAART Causes Bone Loss (03/14/11)
  75. CROI: HAART-induced Immune Reconstitution: A Driving Force Behind Bone Resorption in HIV/AIDS (03/13/11)
  76. CROI: Changes in Bone Biomarkers in ARV-naïve HIV+ Men Randomized to NVP/LPV/r or AZT/3TC/LPV/r Help Explain Limited Loss of Bone Mineral Density over the First 12 Months after ART Initiation (03/13/11)
  77. Increased Rates of Bone Fracture among HIV-Infected Persons in the HIV Outpatient Study (HOPS) Compared with the US General Population, 2000-2006 - pdf attached - (03/12/11)
  78. CROI: Bone Effects of Rosiglitazone in HIV-Infected Patients with Lipoatrophy (03/11/11)
  79. CROI: Fracture Risk Highest in First 2 Years of ART--and Maybe in First 12 Weeks written by Mark Mascolini - (03/2/11)
  80. CROI: Higher Fracture Rate With HIV + HCV Than With Either Virus Alone written by Mark Mascolini - (03/1/11)
  81. Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial - pdf attached - (02/18/11)
  82. Effect of vitamin D supplementation on muscle strength: a systematic review and meta-analysis - pdf attached - (02/14/11)
  83. Relationship between bone mineral density changes and risk of fractures among patients receiving calcium with or without vitamin D supplementation: a meta-regression - pdf attached - (02/14/11)
  84. Bone Mineral Density and Testicular Failure: Evidence for a Role of Vitamin D 25-Hydroxylase in Human Testis - pdf attached - (01/27/11)
  85. IAC: HCV Co-infection is Associated with a High Risk of Osteoporotic Fractures Among HIV Patients - (07/26/10)
  86. IAC: 80% Prevalence of hypovitaminosis D and factors associated in a sample of HIV patients in Italy - (07/26/10)
  87. IAC: Oral Poster discussion: Shining Light on Vitamin D deficiency - (07/26/10)
  88. The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know - pdf attached - (01/27/11)
  89. What Do We Tell Our Patients about Calcium and Vitamin D Supplementation? EDITORIAL pdf attached - (01/27/11)
  90. New Research Finds HIV causes rapid aging in key infection-fighting cells: "Successful ART treatment does not fully reconstitute the CD31-CD4+ na´ve T-cell subset"- pdf attached - (01/27/11)
  91. Low Vitamin D among HIV-Infected Adults: Prevalence of and Risk Factors for Low Vitamin D Levels in a Cohort of HIV-Infected Adults and Comparison to Prevalence among Adults in the US General Population - pdf attached (this was presented in poster at CROI) - (01/14/11)
  92. The Effect of Antiretrovirals on Vitamin D - pdf attached - (01/14/11)
  93. No link between vitamin-D levels and cardiovascular mortality in sunny California- - 3 articles questioning benefit of vitamin D for chronic diseases - (12/22/10)
  94. Atypical Femoral Fractures and Bisphosphonate Use - (12/09/10)
  95. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study - pdf attached - (12/01/10)
  96. Novel Bone Drug (odanacatib, cathepsin K inhibitor) Found Safe After Four Years - (10/22/10)
  97. Comparison of Changes in Bone Density and Turnover with Abacavir-Lamivudine versus Tenofovir-Emtricitabine in HIV-Infected Adults: 48-Week Results from the ASSERT Study - pdf attached - (10/22/10)
  98. Low Bone Mineral Density with Tenofovir: Does Statistically Significant Mean Clinically Significant? - EDITORIAL COMMENTARY - (10/22/10)
  99. Mixed Analysis Findings Adds to Evidence of Unusual Bone Fractures and Bisphosphonates - (10/21/10)
  100. Early Bone Loss Marker Predicts Fracture Risk Later - (10/21/10)
  101. Vitamin D Has Retinopathy Link - (10/21/10)
  102. Vitamin D Levels Linked to Mortality - (10/21/10)
  103. Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C - (10/21/10)
  104. Teriparatide for Bone Loss in the Jaw - Editorial - (10/19/10)
  105. Teriparatide Therapy for Alendronate-Associated Osteonecrosis of the Jaw - (10/18/10)
  106. Teriparatide and Osseous Regeneration in the Oral Cavity - (10/18/10)
  107. Symposium: Optimizing Vitamin D Intake for Populations with Special Needs: Barriers to Effective Food Fortification and Supplementation - (10/18/10)
  108. Vitamin D levels lower in African-Americans - (10/17/10)
  109. Symposium: Optimizing Vitamin D Intake for Populations with Special Needs: Barriers to Effective Food Fortification and Supplementation - (10/16/10)
  110. Racial differences in the relationship between vitamin D, bone mineral density, and parathyroid hormone in the National Health and Nutrition Examination Survey - pdf attached - (10/16/10)
  111. Osteoporosis: adherence needs to top two-thirds to cut fracture risk - (09/27/10)
  112. Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues - pdf attached - (09/25/10)
  113. Body Fat & Bone Loss: lipoatrophy & belly fat accumulation BOTH lead to bone loss - (09/25/10)
  114. Bisphosphonates and Reports of Unusual Broken Bones in the Femur (Thigh Bone) - (09/24/10)
  115. Bone Disease in HIV Infection: A Practical Review and Recommendations for HIV Care Providers - pdf attached - "we recommend a DXA scan for all HIV-infected post-menopausal women and men >50 years" - (09/17/10)
  116. ASBMR Task Force Report on Atypical Femoral Fractures Published in the JBMR - (09/17/10)
  117. ICAAC: High Rates of Bone Loss and Progression With HIV in Longitudinal Study - Written by Mark Mascolini - (09/15/10)
  118. ICAAC: Vitamin D Deficiency & Bone Loss in Europe - (09/14/10)
  119. No Cancer Risk with Bisphosphonates - (09/02/10)
  120. Bisphosphonates Tied to Esophageal Cancer - (09/02/10)
  121. High prevalence of reduced bone mineral density in primary HIV-1-infected men - (08/29/10)
  122. High prevalence of reduced bone mineral density in primary HIV-1-infected men - publication pdf attached - (08/08/10)
  123. Calcium supplements boost heart-attack risk: Meta-analysis - (08/06/10)
  124. TZD Use Linked to Fracture Risk in Women 50 and Older - (08/06/10)
  125. Risk of MI May Go Up With Calcium Supplements - (08/06/10)
  126. IAC: High Prevalence of Bone Demineralization in a Cohort of HIV-Infected Postmenopausal Women - (08/06/10)
  127. IOF position statement: vitamin D recommendations for older adults - Position Paper - (07/23/10)
  128. Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats - pdf attached - (07/22/10)
  129. Common genetic determinants of vitamin D insufficiency: a genome-wide association study - (06/15/10)
  130. FDA: Possible Fracture Risk with High Dose, Long-term Use of Proton Pump Inhibitors - (05/26/10)
  131. Low Vitamin D Levels Associated with Genotype 1, Fibrosis, Inflammation, with SVR, with waist circumference, Low HDL - (05/18/10)
  132. "A higher 25(OH)D (vit D) was associated with better dietary quality, lower %BF (body fat, central obesity), and lower number of MetD (metabolic disturbances including CRP, glucose)"...dairy in diet helped vit D levels - pdf attached - (05/13/10)
  133. Denosumab Inhibits Bone Loss in RA - (05/13/10)
  134. High-Dose Vitamin D Supplementation, Too Much of a Good Thing? - (05/12/10)
  135. EASL: Vitamin D Improves SVR in Naïve Genotype 1 with Peg/Rbv - (04/16/10)
  136. Effect of Osteoporosis Treatment on Mortality: A Meta-Analysis - (03/28/10)
  137. Proton-Pump Inhibitor Use Is Not Associated With Osteoporosis or Accelerated Bone Mineral Density Loss - (03/28/10)
  138. Evolving Data about Subtrochanteric Fractures and Bisphosphonates-EDITORIAL - (03/25/10)
  139. Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur - (03/25/10)
  140. FDA Drug Safety Communication: Ongoing safety review of oral bisphosphonates and atypical subtrochanteric femur fractures - (03/12/10)
  141. Quantity vs. Quality: Long-Term Use of Bone-Building Osteoporosis Drugs May Affect Quality and Structural Integrity of Bone - (03/12/10)
  142. Long-term use of bisphosphonates may increase risk of atypical fractures: studies - (03/12/10)
  143. CROI: Longitudinal Analysis of Bone Mineral Density in Aging Men With or at Risk for HIV Infection: heroin causes bone loss; accelerated bone loss progressed over 3 years in HIV+ - (03/10/10)
  144. CROI: Changes in Bone Mineral Density: two-years follow-up of the ANRS CO3 Aquitaine Cohort - Bone Metabolism Evolves- in 11% from osteopenia to osteoporosis and to osteopenia, bone markers worsen in 41% - (03/10/10)
  145. CROI: Bone & Limb Fat Outcomes in ACTG5202- More Bone Loss With TDF/FTC Than ABC/3TC - written by Mark Mascolini - (02/23/10)
  146. CROI:Bone Fractures at CROI 2010 - see slides below - (02/23/10)
  147. CROI: Bone Disease: Risk Factors - (02/22/10)
  148. Bone Loss in HIV+ Premenopausal Women & Fracture Risk - (02/04/10)
  149. Visceral Fat Causes Inflammation and Cytokines Leading To Bone Loss - (01/16/09)
  150. HIV-Infected Postmenopausal Women at High Risk for Bone Fractures - pdf publication attached - (01/11/09)
  151. Exploring a Low-Acid Diet for Bone Health - (11/25/09)
  152. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial - (10/04/09)
  153. Fall Prevention: how much vitamin D do you need? - (10/04/09)
  154. Vitamin D Improves Muscle Function - (09/29/09)
  155. Sex Steroids & Fracture Risk in Men - (09/06/09)
  156. Lipodystrophy & Bone Loss - (09/06/09)
  157. Vitamin D, Diabetes & Bone in African-Americans - (09/06/09)
  158. A Potential Role for Vitamin D on HIV Infection? - (09/03/09)
  159. Vitamin D Immunomodulator EDITORIAL - (09/03/09)
  160. Low Vitamin D Levels Increased Risk for HIV MTCT: Perinatal Outcomes, Including Mother-to-Child Transmission of HIV, and Child Mortality and Their Association with Maternal Vitamin D Status in Tanzania - (09/03/09)
  161. Oxidized lipids enhance RANKL production by T lymphocytes: Implications for lipid-induced bone loss - pdf attached - (08/27/09)
  162. The clot thickens-oxidized lipids and thrombosis - (08/26/09)
  163. Oxidized lipids: a key to heart disease? - (08/26/09)
  164. Aging/HIV Clinical Care & Research - New IDSA Guidelines - (08/26/09)
  165. Thyroid Dysfunction, Hypogonadism, Testosterone, Bone, Prostate Cancer, HIV & HAART - (08/26/09)
  166. Aging & HIV Recognized as a Serious Concern But No Real Discussion, Still Ignored. 2007 NIH Workshop recommendations - (08/26/09)
  167. A serum 25-hydroxyvitamin D level below 50 nmol/l has been associated with increased body sway and a level below 30 nmol/l with decreased muscle strength. - (08/18/09)
  168. Vitamin D deficiency, muscle function, and falls in elderly people1,2 Review Article - (08/18/09)
  169. Thiazolidinediones and Fractures in Men and Women - (08/12/09)
  170. Bone Guidelines Excerpted From New IDSA Guidelines- pdf of full paper attachedá - (08/12/09)
  171. Prevalence and Associations of 25-Hydroxyvitamin D Deficiency in US Children: NHANES 2001-2004 - pdf of published report attached - (08/12/09)
  172. Bone mineral density and disorders of mineral metabolism in chronic liver disease: Cirrhotics Have Low Bone Density & Low Vitamin D Levels - (08/04/09)
  173. -2.5% Bone Loss Over 96 Weeks on PI or NNRTI in study reported - (08/04/09)
  174. 5th IAS: Highly prevalent vitamin D deficiency and insufficiency among an urban cohort of human immunodeficiency virus (HIV)-infected men under care - (07/28/09)
  175. 5th IAS: ARTs Cause Bone Loss - (07/28/09)
  176. 5th IAS: Long-Term Bone Loss Similar With PI- and NRTI-Sparing Regimens - written by Mark Mascolini - (07/21/09)
  177. 5th IAS: European Researchers Issuing Guidelines on Bone Disease - (07/19/09)
  178. Metabolic bone disease in HIV infection: HIV, ART Implicated EDITORIAL - (07/02/09)
  179. First line AZT/3TC/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir - (07/02/09)
  180. Monitoring bone mineral density during antiresorptive treatment for osteoporosis - Editorial - (06/27/09)
  181. Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data - (06/27/09)
  182. The Value of Bone Density Testing - (06/27/09)
  183. FDA Approves Zoledronic Acid - Reclast(R) - to Prevent Osteoporosis in Postmenopausal Women With Convenient Less Frequent Dosing, Once Every 2 Years - (06/03/09)
  184. Efavirenz and bone health - (05/22/09)
  185. Sunlight and Vitamin D Both Good for Cardiovascular Health - (04/22/09)
  186. Glucocorticoid-induced osteoporosis: hope on the HORIZON-COMMENT - (04/20/09)
  187. HIV-1 Infection Is Associated With an Earlier Occurrence of a Phenotype Related to Frailty: HIV+ men in MACS 10-Times More Likely to Exhibit Frailty than HIV-negative Men. - (04/20/09)
  188. MACS Frailty/HIV/CD4 Study Misses The Point - (04/20/09)
  189. Osteoporosis Drug Teriparatide Speeds Fracture Healing - (04/20/09)
  190. Vitamin D Deficiency in Older Men - (04/09/09)
  191. Relationships of Serum 25-Hydroxyvitamin D to Bone Mineral Density and Serum Parathyroid Hormone and Markers of Bone Turnover in Older Persons - (04/09/09)
  192. CROI: Osteopenia and Osteoporosis in HIV-infected Patients Are Associated with Reduced Frequency of Central Memory CD8+CD127+ T Cells: T-cell activation/senescence associated with bone loss - (03/05/09)
  193. CROI: HIV-1 Induces Apoptosis in primary Osteoblasts: an Alternative Mechanism in the Osteopenia/Osteoporosis Development - (03/04/09)
  194. CROI: GENDER AND GONADAL FUNCTION DIFFERENCES IN THE PREVALENCE OF BONE MASS REDUCTION: higher rates of osteopenia and osteoporosis for men vs women and at early ages, in their 40s. - (03/04/09)
  195. CROI: Bone/Osteoporosis CROI 2009 Update - written by Todd Brown, MD, PhD (03/04/09)
  196. CROI: Immune Senescence, Activation and Abnormal T cell Homeostasis Despite Effective HAART, A Hallmark of Early Aging in HIV Disease - (03/03/09)
  197. CROI: Changes in Bone Turnover, OPG/RANKL, and Inflammation with ART Initiation: A Comparison of Tenofovir- and Non-Tenofovir-Containing Regimens - (03/03/09)
  198. CROI: Evaluation of peripheral DEXA Bone Densitometry to identify low bone mineral density in HIV- infected men in UK: 60% osteopenia, 13% osteoporosis- median age 41 yrs; t-score/dexa predicts fracture in HIV - (03/03/09)
  199. CROI: Clinical Determinants of Bone Mineral Density (BMD) in Perinatally HIV-Infected Children - (03/03/09)
  200. CROI: Bone Mineral Density in HIV+ Women: Relationship to Body Composition - (03/03/09)
  201. CROI: Preferential Bone Demineralization at the Hip in Treated HIV+ Males: Another Example of Premature Aging? - (03/03/09)
  202. CROI: Determinants (HIV, Cytokines) of Low Bone Density in Postmenopausal HIV+ Women - (03/03/09)
  203. CROI: Short term bone loss in HIV infected premenopausal women - (03/03/09)
  204. CROI: Bone Loss at Baseline and Week 144 in Study 903 TDF vs d4T + EFV (02/23/09)
  205. Vitamin D's Expanding Role EDITORIAL - (02/07/09)
  206. Vitamin D Status and Muscle Function in Post-Menarchal Adolescent Girls - (02/07/09)
  207. Patient Information Page from The Hormone Foundation: Vitamin D, Calcium, and Bone Health - (02/06/09)
  208. Mortality Risk Associated With Low-Trauma Osteoporotic Fracture and Subsequent Fracture in Men and Women - (02/05/09)
  209. High Frequency of Vitamin D Deficiency in Ambulatory HIV-Positive Patients - (02/03/09)
  210. Vitamin D Deficiency in Older Men - (01/30/09)
  211. Annual Zoledronate Increases Bone Density in Highly Active Antiretroviral Therapy-Treated Human Immunodeficiency Virus-Infected Men: A Randomized Controlled Trial - (12/30/08)
  212. Once A Year Zoledronate Bone Therapy Increased Bone Density & T-Scores - (12/30/08)
  213. Thyroid Dysfunction & Bone Disease in HIV & HCV; Thyroid Testing Recommended by UK Group - (12/30/08)
  214. DART: Foot-Fractures in HIV+ Men Written for NATAP by Mark Mascolini - (12/11/08)
  215. The cell biology of bone metabolism - (12/09/08)
  216. Bone Finding May Point to Hope for Osteoporosis - (12/02/08)
  217. 9th Interntl Drug Thrpy HIV: High HIV Load Stymies Calcium Deposition in Bone-Forming Cells - Written by Mark Mascolini - (11/12/08)
  218. 2 New Osteoporosis Drugs in the Works: Biologic Osteoporosis Drugs Denosumab and Odanacatib Show Promise in Clinical Trials - (09/22/08)
  219. Update in Osteoporosis and Metabolic Bone Disorders - (09/22/08)
  220. Denosumab Osteoporosis Trial Finds Patients Transitioned from Alendronate (Fosamax(R)) to Denosumab Achieved Significantly Greater Gains in Bone Mineral Density versus Those Continuing on Alendronate - (09/22/08)
  221. Odanacatib, Merck's Investigational Cathepsin K Inhibitor, Increased BMD Over Two Years at Key Fracture Sites in Phase IIB Study - (09/22/08)
  222. Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women: phase 3 results - (09/22/08)
  223. v
  224. Pharmacologic Treatment of Low Bone Density or Osteoporosis to Prevent Fractures: A Clinical Practice Guideline from the American College of Physicians - (09/18/08)
  225. (Increased) Fracture Risk in Type 2 Diabetes: Update of a Population-Based Study - (09/17/08)
  226. Risk factors for decreased bone density and effects of HIV on bone in the elderly - (09/3/08)
  227. The near absence of osteoporosis treatment in older men with fractures - (09/3/08)
  228. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection [EPIDEMIOLOGY AND SOCIAL] - (09/3/08)
  229. HIV Infection and Bone Mineral Density in Middle-Aged Women - (09/3/08)
  230. Bone and Mineral Metabolism in Human Immunodeficiency Virus Infection - (09/2/08)
  231. Inflammatory Markers and Incident Fracture Risk in Older Men and Women: The Health Aging and Body Composition Study - (09/2/08)
  232. Long-term use of bisphosphonates in the treatment of HIV-related bone pain in perinatally infected pediatric patients [Correspondence] - (08/29/08)
  233. FRAX Bone Treatment Algorithm: A Revised Clinician's Guide to the Prevention and Treatment of Osteoporosis- commentary - (07/15/08)
  234. Serial Assessment of Serum Bone Metabolism Markers Identifies Women with the Highest Rate of Bone Loss and Osteoporosis Risk - (07/15/08)
  235. CLINICIAN'S GUIDE TO PREVENTION AND TREATMENT OF OSTEOPOROSIS (National Osteoporosis Foundation Guidelines) - (07/07/08)
  236. Long-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture - (07/04/08)
  237. Use of Antidepressants and Rates of Hip Bone Loss in Older Women - (07/04/08)
  238. Fracture Prevalence Among HIV-Infected versus Non HIV-Infected Patients in a Large U.S. Healthcare System - (07/02/08)
  239. Association of Pioglitazone Treatment with Decreased Bone Mineral Density in Obese Premenopausal Patients with Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial - (05/22/08)
  240. Guidelines Recommend Screening for Men at Increased Risk for Ostoeporosis. - (05/10/08)
  241. Comparative Efficacy between therapies for bone disease: What We Know, What We Need to Know, and How We Can Get There EDITORIAL - (05/10/08)
  242. Guidelines Recommend Screening for Men at Increased Risk for Ostoeporosis. "Screening for Osteoporosis in Men: A Clinical Practice Guideline from the American College of Physicians" - (05/10/08)
  243. Bone health & Antiepileptic Drugs - (05/02/08)
  244. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy - (05/02/08)
  245. Use of Alendronate and Risk of Incident Atrial Fibrillation in Women - (05/01/08)
  246. Diabetes drugs (glitazones) double fracture risk: Swiss study - (05/01/08)
  247. Gut (liver), inflammation and osteoporosis: basic and clinical concepts - (04/16/08)
  248. Osteoporosis in Men - (04/07/08)
  249. Bone Disease in HIV: study finds, heavily pre-treated patients had Vitamin D deficiency & serum marker abnormalities & perhaps serum markers may be better for assessing patient risk than total BMD by DEXA - (04/03/08)
  250. Osteoporosis and Fractures Missing the Bridge? Commentary - (03/28/08)
  251. Do n-3 fatty acids prevent osteoporosis? - (03/26/07)
  252. Glitazones May Improve Endothelial Function & Weaken Bones At Once - (03/25/08)
  253. Two Genetic Variants Found to be Associated with Increased Risk for Osteoporosis and Fracture - (03/25/08)
  254. CROI: Bone Disease Is Increased in HIV; Cancer Risk Increases with Age & Immune Deficiency - (03/25/08)
  255. Randomized Trial of Once-Weekly PTH(1-84) on Bone Mineral Density and Remodeling - (03/20/08)
  256. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection - (03/20/07)
  257. Effects of Alendronate on BMD and Fracture Risk: The FOSIT Study - (03/17/08)
  258. Osteopenia: intervention & therapy - (03/17/08)
  259. Ten Years' Experience with Alendronate (5, 10 and 20 mg daily) for Osteoporosis in Postmenopausal Women - (03/17/08)
  260. OSTEOPENIA IN HIV: tests and markers to evaluate bone loss - (03/14/08)
  261. Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws - (03/14/08)
  262. Smoking Increases Bone Loss and Decreases Intestinal Calcium Absorption - (03/14/08)
  263. Clinical Use of Serum and Urine Bone Markers in the Management of Osteoporosis - (03/14/08)
  264. 10 vs 5 Years of Bisphosphonate Treatment for Postmenopausal Osteoporosis EDITORIAL - (03/14/08)
  265. The attainment of peak bone mass: what is the relationship between muscle growth and bone growth? - (03/13/08)
  266. Osteoporosis and chronic kidney disease - (03/13/08)
  267. Bone disorders in chronic liver disease - (03/10/08)
  268. Thiazolidinediones: New Evidence of Bone Loss Editorial - (03/03/08)
  269. Thiazolidinedione Treatment Decreases Bone Mineral Density in Type 2 Diabetic Men - (03/03/08)
  270. AZT Enhances Osteoclastogenesis and Bone Loss - (03/03/08)
  271. CROI: Bone Mineral Density (BMD) 96 Weeks after Antiretroviral Therapy (ART) Initiation: A Randomized Trial Comparing Efavirenz (EFV)-Based Therapy to a Lopinavir/ritonavir (LPV/r)-Containing Regimen with Simplification to LPV/r Monotherapy - (02/27/08)
  272. Thiazolidinedione Treatment Decreases Bone Mineral Density in Type 2 Diabetic Men - (02/22/08)
  273. Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C - (02/22/08)
  274. CROI: Risk Factors for Reduced Bone Mineral Density In HIV-Infected Individuals In The Modern HAART Era - (02/22/08)
  275. CROI: Bone Metabolism in HIV: CROI 2008 Update - written by Todd T. Brown, MD, PhD - (02/22/08)
  276. Benefits of 2 Years of Intense Exercise on Bone Density, Physical Fitness, and Blood Lipids in Early Postmenopausal Osteopenic Women - (02/01/08)
  277. New Bone Drug Denosumab in Postmenopausal Women with Low Bone Mineral Density - (01/29/08)
  278. Low Serum Testosterone Caused Fractures, study found - (01/29/08)
  279. Bone Health: calcium, vitamin D - (01/29/08)
  280. Use of Oral Bisphosphonates and the Risk of Aseptic Osteonecrosis: A Nested Case-Control Study - (01/29/08)
  281. Serum 25-Hydroxyvitamin D and Bone Mineral Density in a Racially and Ethnically Diverse Group of Men - (01/29/08)
  282. Muscle mass and bone mineral indices: does the normalized bone mineral content differ with age? - (01/29/08)
  283. Vitamin D Reduces Risk of Fall by 23% - (01/29/08)
  284. Vitamin D: What's Enough? Part II - (01/29/08)
  285. From muscle strength to immunity, scientists find new vitamin D benefits Part 1 - (01/29/08)
  286. Increased Bone Turnover in Patients with Hypercholesterolemia. - (01/29/08)
  287. Muscle mass and bone mineral indices: does the normalized bone mineral content differ with age? - (01/29/08)
  288. New Bone Therapy Denosumab vs Fosamax - (01/25/08)
  289. Bone Loss 62% in HIV+ - (01/23/08)
  290. Factors Associated with Low Bone Mineral Density (BMD) in a Large Cohort of HIV-Infected U.S. Adults - Baseline Results from the SUN Study -CROI 2007 - (01/23/08)
  291. 80% Bone Abnormalities in France Aquitane Cohort, 27% Osteoporosis - (01/23/08)
  292. Incidence of Osteonecrosis of the Jaw in Women With Postmenopausal Osteoporosis in the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Pivotal Fracture Trial - (01/04/08)
  293. Oral Bispohosphonates (Fosomax) Found To protect Against Osteonecrosis of Jaw in Osteoporosis - (01/04/08)
  294. Incidence of Osteonecrosis of the Jaw in Women With Postmenopausal Osteoporosis in the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Pivotal Fracture Trial - (01/04/08)
  295. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV - (11/26/07)
  296. Effects of Continuing or Stopping Alendronate After 5 Years of Treatment - (01/03/07)
  297. Bone Disease in HIV: study finds, heavily pre-treated patients had Vitamin D deficiency & serum marker abnormalities & perhaps serum markers may be better for assessing patient risk than total BMD by DEXA - (05/31/05)
  298. BMD in Older Women Predicts Vertebral Fractures; vertebral fractures reduced survival; a single measure of BMD predicted vertebral factures - (12/18/07)
  299. Effects of chronic liver disease on bone mineral density and bone metabolism markers in postmenopausal women - (11/07/05)
  300. Alendronate, Vitamin D, and Calcium for the Treatment of Osteopenia/Osteoporosis Associated With HIV Infection - (03/21/05)
  301. Bone Loss in Liver Disease
  302. (02/04/02)
  303. Bone Density and HIV Infection David Alain Wohl, MD University of North Carolina AIDS Treatment and Research Unit - April 3, 2002

  305. Bone Abnormalities at ICAAC: Osteoporosis, Osteonecrosis Written for NATAP by Michael Norton, PA-C, Boriken Health Clinic, NYC - Jan 10, 2002

  307. Low-impact exercise can increase bone mass in women
  308. - (10/31/01)
  309. Nucleosides (NRTIs) and Reduced Bone Mineral Density (Osteopenia) - (5/28/2001)
  310. Review of Studies on Bone Problems at ICAAC and Lipodystrophy Workshop
    - (9/22/00)
  311. Osteopenia in HIV Infection